A Phase 1 Study of ADI-001 in B Cell Malignancies

Phase 1 Terminated 34 enrolled Adicet Therapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.

Timeline

Start: 2021-03-04
Primary completion: 2025-02-03
Completion: 2025-02-03

Outcome

Outcome not reported

Stopped: “Terminated - Halted Prematurely”

Publications

Nishimoto KP, Barca T, Azameera A, Makkouk A, Romero JM, Bai L, Brodey MM, Kennedy-Wilde J, Shao H, Papaioannou S, Doan A, Masri C, Hoang NT, Tessman H, Ramanathan VD, Giner-Rubio A, Delfino F, Sharma K, Bray K, Hoopes M, Satpayev D, Sengupta R, Herrman M, Abbot SE, Aftab BT, An Z, Panuganti S, Hayes SM. Allogeneic CD20-targeted gammadelta T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin Transl Immunology. 2022 Feb 2;11(2):e1373. doi: 10.1002/cti2.1373. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADI-001	Cell therapy	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—